Abstract
The prevalence of AMI in PWE increased during the decade. Mortality rates were high among this population, highlighting the need for comprehensive attention to prophylaxis for risk factors and early diagnosis of AMI in PWE by physicians.
Introduction
While epilepsy is primarily managed as a neurological disorder, emerging evidence suggests a complex, bidirectional relationship between epilepsy and cardiovascular health. Seizures can induce acute cardiac stress, and long-term use of certain anti-seizure medications (ASMs) may interfere with lipid metabolism. This study addresses the data gap regarding real-world outcomes by quantifying temporal trends, identifying risk factors, and measuring the clinical and economic burden of comorbid Acute Myocardial Infarction (AMI) in patients with epilepsy (PWE).
Methods
Researchers conducted a retrospective cohort study using the National Inpatient Sample (NIS), the largest all-payer inpatient database in the United States. The analysis included 8,456,098 hospitalizations of patients aged 18+ with an epilepsy diagnosis between 2008 and 2017. Statistical significance was evaluated using the Cochran–Armitage trend test, and multivariable logistic regression was employed to calculate Odds Ratios (ORs) for mortality and risk factors, adjusting for demographics, hospital characteristics, and comorbidities.
Temporal Trends in AMI Prevalence
A primary finding of this study is the divergent trend of AMI prevalence in the epilepsy community compared to the general population. While AMI rates have generally declined in the U.S. due to improved prevention, prevalence among PWE rose from 1,911.7 to 2,529.5 per 100,000 hospitalizations over the study period.
Clinical and Economic Outcomes
The presence of comorbid AMI significantly worsens the prognosis for patients with epilepsy. PWE with AMI faced an in-hospital mortality rate of 13.35%, compared to just 2.5% for those without AMI. After rigorous adjustment, the risk of death was nearly five times higher (OR 4.61; 95% CI: 4.54–4.69).
Beyond clinical outcomes, AMI imposed a substantial economic burden. Comorbid AMI was associated with an average increase in hospital costs of $44,567 and an extended length of stay by approximately 1.69 days.
Risk Factors and Clinical Implications
The strongest predictors for AMI in this population included:
- Atherosclerosis: OR 4.44
- Age ≥75: OR 3.54
- Conduction Disorders: OR 2.21
- Cardiomyopathy: OR 2.11
The rising prevalence of dyslipidemia (from 19.29% to 32.01%) suggests that Enzyme-Inducing Anti-Seizure Medications (EIASMs) may play a role by interfering with cholesterol metabolism. Furthermore, the high mortality rate suggests a potential "tunnel vision" in clinical practice, where a focus on seizure control may lead to delayed diagnosis or less aggressive management of cardiovascular events.
Limitations
The study is limited by its reliance on inpatient data, which may miss "silent" infarctions or deaths occurring outside the hospital. Additionally, the NIS database lacks granularity regarding specific seizure types and medication dosages, preventing the establishment of direct causal links. Future prospective studies are needed to evaluate the cardiovascular safety of various ASM regimens.
Summary updated